Compare · ANGO vs MDLN
ANGO vs MDLN
Side-by-side comparison of AngioDynamics Inc. (ANGO) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANGO and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 90.1x ANGO ($492.9M).
- Over the past year, ANGO is up 7.3% and MDLN is down 17.1% - ANGO leads by 24.4 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 2 for ANGO).
- MDLN has more recent analyst coverage (25 ratings vs 8 for ANGO).
- Company
- AngioDynamics Inc.
- Medline Inc.
- Price
- $11.93-0.13%
- $33.80+0.58%
- Market cap
- $492.9M
- $44.40B
- 1M return
- +5.86%
- -19.55%
- 1Y return
- +7.28%
- -17.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- 2025
- News (4w)
- 2
- 20
- Recent ratings
- 8
- 25
AngioDynamics Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Latest ANGO
- AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
- AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
- AngioDynamics Inc. filed SEC Form 8-K: Other Events
- SEC Form 10-Q filed by AngioDynamics Inc.
- AngioDynamics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
- AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by AngioDynamics Inc.
- AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)